DSS
MCID: DNG001
MIFTS: 43

Dengue Shock Syndrome (DSS)

Categories: Infectious diseases

Aliases & Classifications for Dengue Shock Syndrome

MalaCards integrated aliases for Dengue Shock Syndrome:

Name: Dengue Shock Syndrome 12 54 15 71
Dss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050125
UMLS 71 C0376300

Summaries for Dengue Shock Syndrome

Disease Ontology : 12 A dengue disease that involves the most severe form of dengue fever, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom easy bruising, has symptom blood spots, has symptom bleeding gums, and has symptom nosebleeds. It is accompanied by circulatory collapse, involves hypotension, narrow pulse pressure (less than or equal to 20mm Hg), or frank shock. The shock occurs after two to six days of symptoms, followed by collapse, weak pulse, and blueness around the mouth.

MalaCards based summary : Dengue Shock Syndrome, also known as dss, is related to dengue disease and colitis, and has symptoms including easy bruising, blood spots and bleeding gums. An important gene associated with Dengue Shock Syndrome is THBD (Thrombomodulin), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include endothelial, liver and kidney.

Related Diseases for Dengue Shock Syndrome

Diseases related to Dengue Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 532)
# Related Disease Score Top Affiliating Genes
1 dengue disease 32.4 TNF SULT1A3 SENP8 IFT81 CSPG5 CLEC5A
2 colitis 32.4 TNF IL6 IL1B HLA-DRB1
3 ulcerative colitis 31.8 TNF IL6 IL1RN IL1B HLA-DRB1
4 diarrhea 31.0 TNF IL6 IL1B CD40LG
5 crohn's disease 30.9 TNF IL6 IL1B HLA-DRB1 CCL2
6 proteasome-associated autoinflammatory syndrome 1 30.7 TNF IL6 IL1RN IL1B CCL2
7 non-alcoholic steatohepatitis 30.7 TNF IL6
8 perinatal necrotizing enterocolitis 30.6 TNF IL6 IL1B
9 respiratory failure 30.6 TNF THBD IL6 IL1RN IL1B
10 inflammatory bowel disease 30.6 VEGFA TNF MICB IL6 IL1RN IL1B
11 gastritis 30.6 TNF IL6 IL1RN IL1B
12 bacterial sepsis 30.5 TNF IL6 IL1RN
13 urethritis 30.5 TNF IL6 CD40LG
14 dengue hemorrhagic fever 30.5 VEGFA TNF IL6 HLA-DRB1 HLA-A CMA1
15 cystitis 30.4 VEGFA TNF IL6 CCL2
16 appendicitis 30.4 TNF IL6 IL1B CCL2
17 aspergillosis 30.4 TNF IL6 IL1RN IL1B CD209
18 ileus 30.4 TNF IL6 IL1B CCL2
19 parasitic helminthiasis infectious disease 30.4 TNF IL6 CD40LG
20 autoimmune disease 30.3 TNF IL6 IL1RN IL1B HLA-DRB1 HLA-A
21 myocarditis 30.3 TNF IL6 IL1B CD40LG CCL2
22 japanese encephalitis 30.3 TNF CD209 CCL2
23 disseminated intravascular coagulation 30.3 TNF THBD IL6
24 purpura 30.3 TNF THBD IL6 CD40LG
25 peritonitis 30.3 TNF IL6 IL1B CMA1 CCL2
26 exanthem 30.2 VEGFA TNF SENP8 IL6 IL1RN CD40LG
27 toxic shock syndrome 30.1 TNF IL6 IL1RN IL1B CD40LG
28 sickle cell anemia 30.1 TNF IL6 CD40LG
29 migraine with or without aura 1 30.1 TNF IL6 IL1B CD40LG
30 chronic kidney disease 30.1 VEGFA TNF THBD IL6 CCL2
31 bacterial infectious disease 29.9 TNF IL6 IL1RN IL1B CD40LG CCL2
32 thrombocytopenia 29.9 TNF THBD IL6 IL1RN IL1B CD40LG
33 encephalitis 29.7 TNF IL6 IL1B CD40LG CD209 CCL2
34 multiple sclerosis 29.5 TNF IL6 IL1RN IL1B HLA-DRB1 HLA-A
35 diabetes mellitus 29.0 VEGFA TNF THBD IL6 IL1RN IL1B
36 malaria 28.8 VEGFA TNF THBD SULT1A3 IL6 IL1RN
37 dengue virus 11.8
38 hypertrophic neuropathy of dejerine-sottas 11.5
39 46,xy sex reversal 2 11.5
40 neuropathy, congenital hypomyelinating, 1, autosomal recessive 11.4
41 neuropathy, congenital hypomyelinating, 2 11.4
42 charcot-marie-tooth disease, demyelinating, type 4f 11.2
43 external pathological resorption 10.7 TNF IL6
44 scorpion envenomation 10.6 TNF IL6
45 staphylococcal toxic shock syndrome 10.6 TNF IL1B
46 systemic onset juvenile idiopathic arthritis 10.6 TNF IL1RN IL1B
47 vulvar vestibulitis syndrome 10.6 TNF IL1RN IL1B
48 mesial temporal lobe epilepsy with hippocampal sclerosis 10.6 IL1B HLA-DRB1
49 idiopathic anterior uveitis 10.6 TNF IL6
50 postherpetic neuralgia 10.6 HLA-DRB1 HLA-A

Graphical network of the top 20 diseases related to Dengue Shock Syndrome:



Diseases related to Dengue Shock Syndrome

Symptoms & Phenotypes for Dengue Shock Syndrome

Symptoms:

12
  • easy bruising
  • blood spots
  • bleeding gums
  • nosebleeds

Drugs & Therapeutics for Dengue Shock Syndrome

Drugs for Dengue Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 51-45-6 774
2
Ketotifen Approved Phase 4 34580-13-7, 34580-14-8 3827
3 Neurotransmitter Agents Phase 4
4 Histamine H1 Antagonists Phase 4
5 Dermatologic Agents Phase 4
6
Histamine Phosphate Phase 4 51-74-1 65513
7 Antipruritics Phase 4
8 Histamine Antagonists Phase 4
9 Anti-Allergic Agents Phase 4
10 Pharmaceutical Solutions Phase 3
11
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
12 Gastrointestinal Agents Phase 1
13 Vaccines Phase 1
14 Adjuvants, Immunologic Phase 1
15 Anti-Ulcer Agents Phase 1
16 Immunologic Factors Phase 1
17 Antacids Phase 1

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN) Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 The Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as a Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 The Clinical Efficacy and Safety of a Proprietary Solution Containing Hypertonic Sodium Lactate (Totilac®) Infusion for Resuscitation of Patients With Hemorrhagic Shock Due to Multiple Injuries Completed NCT01433276 Phase 3 Hyperosmolar sodium lactate;Ringer's lactate
4 Phase 1, Placebo-Controlled, Double-Blind, Safety Study of HBV-001 D1 in Healthy Adults Completed NCT00936429 Phase 1
5 Phase 1 Study of the Safety and Immunogenicity of rDEN3/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3 Completed NCT00375726 Phase 1
6 Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-4995, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4 Completed NCT00322946 Phase 1
7 Safety and Immunogenicity of a 2-Dose Regimen of rDEN2/4Δ30 Dengue Vaccine With Boosting at 4 Versus 6 Months Completed NCT00920517 Phase 1
8 A Phase 1 Study To Evaluate The Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue (Serotype 1, 2, 3, and 4) Plasmid DNA Vaccine (TVDV) Formulated With and Without Vaxfectin® Completed NCT01502358 Phase 1
9 Phase 1 Study of the Safety and Immunogenicity of rDEN2/4delta30(ME), a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 2 Completed NCT00094705 Phase 1
10 Phase I Study of the Safety and Immunogenicity of rDEN1delta30, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 1 Completed NCT00089908 Phase 1
11 Phase 1 Study of the Safety and Immunogenicity of rDEN4delta30-200,201, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4 Completed NCT00270699 Phase 1
12 A Phase I Dose Comparison Study of the Safety and Immunogenicity of rDEN3delta30/31‐7164, a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 3 Completed NCT00831012 Phase 1
13 Safety and Immunogenicity of a 2-Dose Regimen of rDEN1delta30 Dengue Serotype 1 Vaccine With Boosting at 4 Versus 6 Months Completed NCT00473135 Phase 1
14 A Phase I Evaluation of the Safety and Immunogenicity of rDEN2/4 Δ30(ME) Dengue Serotype 2 Vaccine Given at 10^1 PFU in Healthy Flavivirus-naïve Adult Subjects Completed NCT01073306 Phase 1
15 A Phase I Evaluation of the Safety and Immunogenicity of the rDEN1∆30 Dengue Serotype 1 Vaccine Given at a Single Dose of 101 PFU in Healthy Flavivirus-naïve Adult Subjects Completed NCT01084291 Phase 1
16 A Phase 1 Evaluation of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixtures TV003 and TV005 in Healthy Flavivirus-Naïve Adult Subjects Completed NCT01436422 Phase 1
17 Evaluation of the Safety and Immunogenicity of Heterologous Dengue Vaccine Administration in Dengue Immune Individuals Completed NCT00458120 Phase 1
18 A Phase 1 Evaluation of the Safety and Immunogenicity of Five Admixtures of TetraVax-DV, a Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine, in Healthy Flavivirus-naïve Adult Subjects Completed NCT01072786 Phase 1
19 Phase I Evaluation of the Safety and Immunogenicity of rDEN4delta30 Lot# 109A, a Live Attenuated DEN4 Vaccine, in Healthy Flavivirus-naïve Adult Volunteers. Completed NCT00919178 Phase 1
20 Factors Associated With Poor Dengue Outcomes in Malaysia Completed NCT02510690
21 Adult Dengue Platelet Study Completed NCT01030211
22 Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore Completed NCT04048837
23 The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia Completed NCT02510638
24 Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection Recruiting NCT00688389

Search NIH Clinical Center for Dengue Shock Syndrome

Genetic Tests for Dengue Shock Syndrome

Anatomical Context for Dengue Shock Syndrome

MalaCards organs/tissues related to Dengue Shock Syndrome:

40
Endothelial, Liver, Kidney, Heart, T Cells, Monocytes, Bone

Publications for Dengue Shock Syndrome

Articles related to Dengue Shock Syndrome:

(show top 50) (show all 986)
# Title Authors PMID Year
1
Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. 54 61
17006283 2006
2
Recombinant non-structural 1 (NS1) protein of dengue-2 virus interacts with human STAT3beta protein. 54 61
15878791 2005
3
Cytokine patterns during dengue shock syndrome. 54 61
14656693 2003
4
The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. 54 61
11858187 2002
5
Daily Dengue Severity Score to Assess Severe Manifestations. 61
31725549 2020
6
Genetic risk for dengue hemorrhagic fever and dengue fever in multiple ancestries. 61
31901861 2020
7
Interferon lambda 1 is associated with dengue severity in Thailand. 61
31981768 2020
8
Mast cell mediators in relation to dengue severity: A systematic review and meta-analysis. 61
31709696 2020
9
Aedes aegypti Immune Response and Its Potential Impact on Dengue Virus Transmission. 61
31738698 2020
10
The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model. 61
31942645 2020
11
Molecular Signatures of Dengue Virus-Specific IL-10/IFN-γ Co-producing CD4 T Cells and Their Association with Dengue Disease. 61
31875555 2019
12
Identification of inhibitors of dengue viral replication using replicon cells expressing secretory luciferase. 61
31678478 2019
13
Severe Dengue and Associated Hemophagocytic Lymphohistiocytosis in PICU. 61
31353429 2019
14
Clinical Course and Management of Dengue in Children Admitted to Hospital: A 5 Years Prospective Cohort Study in Jakarta, Indonesia. 61
31738330 2019
15
Myocarditis Prevalence in Paediatric Dengue Infection: A Prospective Study in Tertiary Hospital in Yogyakarta, Indonesia. 61
31006000 2019
16
Dengue proteins with their role in pathogenesis, and strategies for developing an effective anti-dengue treatment: A review. 61
31784997 2019
17
Dengue Fever in the Darfur Area, Western Sudan. 61
31625864 2019
18
Extensive genomic recoding by codon-pair deoptimization selective for mammals is a flexible tool to generate attenuated vaccine candidates for dengue virus 2. 61
31539771 2019
19
Discovery of a small molecule inhibitor targeting dengue virus NS5 RNA-dependent RNA polymerase. 61
31738758 2019
20
De novo design approaches targeting an envelope protein pocket to identify small molecules against dengue virus. 61
31472473 2019
21
Dengue Virus M Protein Promotes NLRP3 Inflammasome Activation To Induce Vascular Leakage in Mice. 61
31413130 2019
22
Combination of Modified NS1 and NS3 as a Novel Vaccine Strategy against Dengue Virus Infection. 61
31451673 2019
23
Serine protease inhibitor AEBSF reduces dengue virus infection via decreased cholesterol synthesis. 61
31386864 2019
24
Genetic diversity and evolutionary dynamics of dengue isolates from India. 61
31803801 2019
25
Impact of population displacement and forced movements on the transmission and outbreaks of Aedes-borne viral diseases: Dengue as a model. 61
31226251 2019
26
The Association between Obesity and Severity of Dengue Hemorrhagic Fever in Children at Wangaya General Hospital. 61
31666844 2019
27
Dengue vaccine development: Global and Indian scenarios. 61
30684747 2019
28
[Travel Related Fever and Rash: Two Cases of Dengue Fever]. 61
31414637 2019
29
Association of ABO blood groups with dengue fever and its complications in a tertiary care hospital. 61
31579269 2019
30
Buffered solutions versus 0.9% saline for resuscitation in critically ill adults and children. 61
31334842 2019
31
Prostasin Impairs Epithelial Growth Factor Receptor Activation to Suppress Dengue Virus Propagation. 61
30476206 2019
32
Increased Carotid Intima-Media Thickness in Children with a History of Dengue Hemorrhagic Fever. 61
30675845 2019
33
Protein Disulfide Isomerase Inhibitor Suppresses Viral Replication and Production during Antibody-Dependent Enhancement of Dengue Virus Infection in Human Monocytic Cells. 61
30781856 2019
34
Circulation of single serotype of Dengue Virus (DENV-3) in New Delhi, India during 2016: A change in the epidemiological trend. 61
30274896 2019
35
Dengue Virus Infection Activates Interleukin-1β to Induce Tissue Injury and Vascular Leakage. 61
31824450 2019
36
Zika Virus Induced More Severe Inflammatory Response Than Dengue Virus in Chicken Embryonic Livers. 61
31191474 2019
37
Selection-based design of in silico dengue epitope ensemble vaccines. 61
29931821 2019
38
Clinical Characteristic and Risk Factors of Acute Kidney Injury among Dengue Viral Infections in Adults: A Retrospective Analysis. 61
30814788 2019
39
Dengue Non-structural Protein 5 Polymerase Complexes With Promyelocytic Leukemia Protein (PML) Isoforms III and IV to Disrupt PML-Nuclear Bodies in Infected Cells. 61
31456950 2019
40
3-Trifluoromethylpyrazolones derived nucleosides: Synthesis and antiviral evaluation. 61
30929566 2019
41
Need for guidelines for the combined management of pregnancy and dengue: a retrospective study from an Indian tertiary care maternity hospital. 61
30270767 2019
42
Clinical Course and Management of Dengue in Children Admitted to Hospital; A 5 Years Prospective Cohort Study in Jakarta, Indonesia. 61
30640199 2019
43
[Winners of globalization: dengue viruses and Japanese encephalitis virus-Diseases in neurology]. 61
30251003 2018
44
Improving the safety of high-dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin. 61
29768710 2018
45
Plectin is Required for Trans-Endothelial Permeability: A Model of Plectin Dysfunction in Human Endothelial Cells After TNF-α Treatment and Dengue Virus Infection. 61
30365215 2018
46
Immune-mediated neurological manifestations of dengue virus- a study of clinico-investigational variability, predictors of neuraxial involvement, and outcome with the role of immunomodulation. 61
30504556 2018
47
Baseline Characterization of Dengue Epidemiology in Yogyakarta City, Indonesia, before a Randomized Controlled Trial of Wolbachia for Arboviral Disease Control. 61
30226138 2018
48
Let-7e inhibits TNF-α expression by targeting the methyl transferase EZH2 in DENV2-infected THP-1 cells. 61
29768655 2018
49
Dengue shock syndrome complicated with acute liver failure and kidney injury, infective endocarditis, and deep vein thrombosis: a case report. 61
30373645 2018
50
Serum fatty acids and progression from dengue fever to dengue haemorrhagic fever/dengue shock syndrome. 61
30105961 2018

Variations for Dengue Shock Syndrome

Expression for Dengue Shock Syndrome

Search GEO for disease gene expression data for Dengue Shock Syndrome.

Pathways for Dengue Shock Syndrome

Pathways related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 VEGFA TNF MICB IL6 IL1RN IL1B
2
Show member pathways
13.31 VEGFA TNF IL6 IL1RN IL1B HLA-DRB1
3
Show member pathways
12.91 VEGFA TNF MICB IL6 IL1B HLA-A
4
Show member pathways
12.81 VEGFA TNF IL6 IL1B HLA-DRB1 HLA-A
5 12.76 TNF IL6 IL1B HLA-DRB1 HLA-A CCL2
6
Show member pathways
12.74 TPSAB1 TNF IL6 IL1B HLA-DRB1 HLA-A
7 12.56 TNF IL1RN IL1B CD40LG CCL2
8 12.33 TNF IL6 HLA-DRB1 HLA-A
9
Show member pathways
12.32 TNF IL6 IL1B CCL2
10
Show member pathways
12.31 TNF IL6 IL1B CCL2
11
Show member pathways
12.25 TNF IL1B HLA-DRB1 CD40LG
12 12.23 TNF IL6 IL1B CCL2
13
Show member pathways
12.21 TNF IL6 IL1RN IL1B
14 12.21 TNF IL6 IL1B HLA-DRB1 CD209
15
Show member pathways
12.2 TNF IL6 IL1B CD209
16 12.14 VEGFA TNF IL6 IL1RN IL1B
17 12.05 VEGFA TNF THBD IL1B CCL2
18 12 TNF IL6 IL1B CCL2
19 12 TNF IL6 IL1B CCL2
20 11.95 TNF IL6 IL1B CCL2
21 11.95 VEGFA TNF IL6 IL1B CCL2
22 11.88 TNF IL6 IL1B HLA-DRB1
23 11.74 TNF IL6 IL1B
24 11.72 TNF THBD IL6 IL1B CD209
25 11.65 TNF IL6 IL1RN IL1B CCL2
26 11.6 TNF IL6 IL1B
27
Show member pathways
11.57 VEGFA TNF IL6 IL1B CD40LG
28 11.52 TNF IL1B CCL2
29 11.52 TNF IL6 IL1B CMA1 CCL2
30 11.48 TNF IL6 IL1B
31 11.4 VEGFA TNF IL6 IL1B HLA-DRB1 CCL2
32 11.39 TNF IL6 IL1B
33 11.35 TNF IL6 IL1B
34 11.35 TNF IL6 IL1B CD40LG CCL2
35 11.34 THBD IL6 CCL2
36 11.29 TNF IL6 IL1B
37 11.27 TNF IL6 IL1B
38 11.24 TNF IL6 IL1B HLA-DRB1
39 11.24 TNF IL6 IL1RN IL1B CCL2
40 11.17 VEGFA TNF THBD PLCE1 IL6 IL1B
41 11.02 TNF PLCE1 IL6 IL1B CD40LG CCL2
42 10.95 TNF IL1B CCL2

GO Terms for Dengue Shock Syndrome

Cellular components related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 VEGFA TPSAB1 TNF IL6 IL1RN IL1B
2 extracellular space GO:0005615 9.7 VEGFA TPSAB1 TNF THBD MICB IL6
3 external side of plasma membrane GO:0009897 9.65 TNF MICB HLA-DRB1 CD40LG CD209
4 cell surface GO:0009986 9.32 VEGFA TNF THBD MICB HLA-DRB1 HLA-A

Biological processes related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.24 VEGFA PLCE1 IL6 IL1RN IL1B CSPG5
2 inflammatory response GO:0006954 9.91 TNF IL6 IL1RN IL1B CD40LG CCL2
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 TNF IL6 IL1B CD40LG
4 positive regulation of JNK cascade GO:0046330 9.81 TNF IL1RN IL1B
5 neutrophil chemotaxis GO:0030593 9.81 IL1RN IL1B CCL2
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 VEGFA TNF IL6
7 cellular response to organic cyclic compound GO:0071407 9.79 TNF IL1B CCL2
8 response to glucocorticoid GO:0051384 9.78 TNF IL6 IL1RN
9 humoral immune response GO:0006959 9.77 TNF IL6 CCL2
10 cellular response to lipopolysaccharide GO:0071222 9.77 TNF IL6 IL1RN IL1B CCL2
11 antigen processing and presentation GO:0019882 9.71 HLA-DRB1 HLA-A CD209
12 protein kinase B signaling GO:0043491 9.69 TNF IL1B CCL2
13 lipopolysaccharide-mediated signaling pathway GO:0031663 9.67 TNF IL1B CCL2
14 positive regulation of chemokine biosynthetic process GO:0045080 9.63 TNF IL1B
15 negative regulation of neurogenesis GO:0050768 9.63 TNF IL6 IL1B
16 negative regulation of lipid storage GO:0010888 9.62 TNF IL6
17 positive regulation of T cell proliferation GO:0042102 9.62 IL6 IL1B CD40LG CD209
18 regulation of establishment of endothelial barrier GO:1903140 9.6 TNF IL1B
19 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.58 IL6 IL1RN
20 positive regulation of glial cell proliferation GO:0060252 9.58 TNF IL6 IL1B
21 regulation of immunoglobulin secretion GO:0051023 9.57 TNF CD40LG
22 positive regulation of fever generation GO:0031622 9.56 TNF IL1B
23 positive regulation of interleukin-6 production GO:0032755 9.56 TNF IL6 IL1RN IL1B
24 sequestering of triglyceride GO:0030730 9.52 TNF IL1B
25 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 TNF IL1B
26 cytokine-mediated signaling pathway GO:0019221 9.43 VEGFA TNF IL6 IL1RN IL1B CCL2
27 positive regulation of neuroinflammatory response GO:0150078 9.33 TNF IL6 IL1B
28 immune response GO:0006955 9.28 TNF MICB IL6 IL1RN IL1B HLA-DRB1

Molecular functions related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.33 HLA-DRB1 CLEC5A CD209
2 cytokine activity GO:0005125 9.17 VEGFA TNF IL6 IL1RN IL1B CD40LG
3 peptide antigen binding GO:0042605 9.13 HLA-DRB1 HLA-A CD209

Sources for Dengue Shock Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....